KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Current Deferred Revenue (2018 - 2025)

Aurinia Pharmaceuticals' Current Deferred Revenue history spans 7 years, with the latest figure at $3.7 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 66.19% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $3.7 million, down 66.19%, while the annual FY2025 figure was $3.7 million, 66.19% down from the prior year.
  • Current Deferred Revenue reached $3.7 million in Q4 2025 per AUPH's latest filing, down from $4.6 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $11.0 million in Q4 2024 to a low of $190000.0 in Q4 2021.
  • Average Current Deferred Revenue over 5 years is $4.4 million, with a median of $4.5 million recorded in 2024.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 1556.84% in 2022, then crashed 66.19% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $190000.0 in 2021, then surged by 1556.84% to $3.1 million in 2022, then surged by 52.89% to $4.8 million in 2023, then soared by 128.59% to $11.0 million in 2024, then plummeted by 66.19% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Current Deferred Revenue are $3.7 million (Q4 2025), $4.6 million (Q3 2025), and $5.5 million (Q2 2025).